Immunicum’s ilixadencel successful in kidney cancer
The drug achieved complete tumour responses in five out of 45 metastatic kidney cancer patients, compared to one in 25.
Read More
Tag: Sutent
Five new medicines backed for EU approval
Five therapies have been backed for approval in the European Union, including two orphan medicines addressing rare conditions.
Read More
FDA widens scope of Pfizer’s Sutent in kidney cancer
The US Food and Drug Administration has cleared Pfizer’s Sutent for adjuvant treatment of adults at a high risk of their kidney cancer returning after a kidney has been removed.
Read More
Mixed results for BMS’ Opdivo, Yervoy combo in kidney cancer
A combination of Bristol-Myers Squibb’s Opdivo and Yervoy has failed to significantly improve progression-free survival (PFS) compared to Pfizer’s Sutent in patients with renal cancer.
Read More
NICE backs Afinitor, Sutent for neuroendocrine tumours
Novartis’ Afinitor and Pfizer’s Sutent have received backing from the National Institute for Health and Care Excellence as cost-effective treatment options for certain neuroendocrine tumours (NETs).
Read More
Data backs broader use of Pfizer’s Sutent in kidney cancer
A Phase III study pitting adjuvant use of Pfizer’s Sutent against a placebo in patients with kidney cancer has met its primary endpoint of showing improved disease-free survival (DFS) in those taking the drug.
Read More
- CERo reports encouraging early data from phase 1 trial of CER‑1236
- ENA Respiratory begins dosing in phase 2 study of INNA‑051 nasal spray
- Argo Biopharma doses first patient in phase 2b trial of BW‑20829
- Akari files new patent and advances second ADC targeting CEACAM5
- BioMed X launches kidney disease project in partnership with the government of Barbados
